Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $111.00
Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...
“Astonishing” – Scientists Unveil First Blueprint of the Most Complex Molecular Machine in Human Biology
Researchers unveil the inner mechanisms of the most intricate and complex molecular machine in human biology. Scientists at ...
New Atlas2d
RNA therapy an effective alternative to lifelong, painful eye injections
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
Bizcommunity3d
Leadership shakeup at Moderna ahead of major vaccine rollouts
Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Acsh.org4d
Don’t Be Afraid of mRNA Vaccines
With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...
BMJ4d
The rapid rise of the UK’s cancer vaccine trials
The UK is making progress in developing cancer vaccines, but there are still challenges ahead, Chris Baraniuk reports The UK is on its way to becoming a hotbed of cancer vaccine trials. In May this ...
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...
RNA editing promises to go where DNA editing can’t
Cells synthesise messenger RNA (mRNA) using instructions in DNA and then ‘read’ instructions from the mRNA to make functional ...